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Abstract
Background: Genetic variation contributes to differences in pain sensitivity and response to
different analgesics. Catecholamines are involved in the modulation of pain and are partly
metabolized by the catechol-O-methyltransferase (COMT) enzyme. Genetic variability in the
COMT gene may therefore contribute to differences in pain sensitivity and response to analgesics.
It is shown that a polymorphism in the COMT gene, Rs4680 (Val158Met), influence pain sensitivity
in human experimental pain and the efficacy for morphine in cancer pain treatment. In this study
we wanted to investigate if variability in other regions in the COMT gene also contributes to
interindividual variability in morphine efficacy.
Results: We genotyped 11 single nucleotide polymorphisms (SNPs) throughout the COMT gene,
and constructed haplotypes from these 11 SNPs, which were in Hardy-Weinberg equilibrium. We
compared both genotypes and haplotypes against pharmacological, demographical and patient
symptoms measurements in a Caucasian cancer patient cohort (n = 197) receiving oral morphine
treatment for cancer pain. There were two frequent haplotypes (34.5% and 17.8%) in our cohort.
Multivariate analyses showed that patients carrying the most frequent haplotype (34.5%) needed
lower morphine doses than patients not carrying the haplotype, with a reduction factor of 0.71 (p
= 0.005). On the allele level, carriers of alleles for six of the SNPs show weak associations in respect
to morphine dose and the alleles associated with the lowest morphine doses constitute part of the
most frequent haplotype.
Conclusion: This study suggests that genetic variability in the COMT gene influence the efficacy of
morphine in cancer patients with pain, and that increased understanding of this variability is reached
by expanding from analyses of single SNPs to haplotype construction and analyses.
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Background
One of the genes in which variability is believed to con-
tribute to differences in pain sensitivity and response to
analgesics is the catechol-O-methyltransferase (COMT) gene
[1-3]. The COMT enzyme metabolises catecholamines
such as dopamine, noradrenaline and adrenaline. The
most studied single nucleotide polymorphism (SNP) in
the COMT gene is the Rs4680, also known as Val158Met.
This polymorphism causes a substitution from a valine
(Val) to a methionine (Met) at amino acid position 158,
leading to a three- to four-fold reduced activity of the
COMT enzyme [4]. Because of the influence on COMT
activity by the Rs4680 (Val158Met) SNP and the well
established involvement of catecholamines in pain per-
ception [5-7], several studies have investigated if this SNP
can explain interindividual variability in pain perception
and efficacy of analgesics. Zubieta et al., demonstrated
that individuals with the Met/Met genotype had higher
sensory and affective ratings of pain and a higher regional
density of mu opioid receptors in the brain [1]. The
Rs4680 (Val158Met) SNP has also been shown to influ-
ence efficacy of morphine used for cancer pain, for which
the Met/Met genotype group needed lower morphine
doses than Val/Val genotype group [2]. Results from these
two studies are intriguing since individuals with the Met/
Met genotype report higher pain ratings, but need less
morphine. However, as authors discuss [2], the increase of
mu opioid receptor density seen in Met/Met genotype
individuals [1], may explain why morphine is more effec-
tive in individuals carrying this genotype.
Other researchers have investigated other SNPs across the
COMT gene and shown that other regions of the gene may
also contribute to pain perception [3,8] and influence
morphine-related side-effects [9]. Diatchenko et al., iden-
tified three genetic variants (haplotypes) in the COMT
gene and designated them as low pain sensitivity (LPS),
average pain sensitivity (APS) and high pain sensitivity
(HPS) haplotypes. The Rs4680 (Val158Met) polymor-
phism was one of four SNPs included in their haplotype
analyses. The authors argue that the Rs4680 (Val158Met)
SNP cannot account for the observed variations in pain
perception alone, since both the LPS and HPS haplotypes
possess the G allele that codes for the more stable Val var-
iant of the COMT enzyme [3]. Kim et al., analysed 13
SNPs in the COMT gene and their association to acute
post-surgical pain in humans [8]. The authors found that
the Rs740603 polymorphism showed significant associa-
tion with maximum post-operative pain rating, but did
not observe any association between other SNPs, includ-
ing the Rs4680 (Val158Met) SNP, and pain score. Ross et
al., found that a SNP in intron 1 (Rs740603) and a haplo-
type, defined by SNPs in the promoter region and intron
1, were significantly associated with drowsiness and con-
fusion or hallucinations in a cancer patient cohort treated
with morphine. In the study by Ross et al., the Rs4680
(Val158Met) SNP did not influence the risk for morphine
induced adverse effect [9].
All the three studies cited above that have investigated
multiple SNPs in the COMT gene have either pain percep-
tion or the risk for opioid adverse effects as the primary
endpoint in the study [3,8,9]. No studies have investi-
gated if other SNPs than the Rs4680 (Val158Met) in the
COMT gene are important for the analgesic efficacy of
morphine. Therefore, in a patient cohort in which we have
previously shown that the Rs4680 (Val158Met) polymor-
phism influences the efficacy of morphine for cancer pain
[2], we investigated if variability in other regions in the
COMT gene also contribute to interindividual variability
in morphine efficacy. In addition to examining the effect
from each individual SNP we constructed long haplotypes
in order to study composite effect from combinations of
11 SNPs along the gene.
Results
DNA from 197 patients receiving oral morphine treat-
ment for cancer pain was analysed in this study.
Genotype and haplotype distribution
A schematic presentation of the 11 SNPs analysed in the
COMT gene is shown in Figure 1. The genotype frequen-
cies, allele frequencies and allele carriage for all 11 SNPs
analysed are shown in Table 1. All SNPs were in Hardy-
Weinberg equilibrium. The long haplotypes constructed
from the 11 SNPs in the COMT gene are shown in Table
2. The frequencies of the two most common haplotypes
were 34.5% and 17.8%. Fourteen different haplotypes
with a frequency of > 1% described 91% of the popula-
tion. We designated the haplotypes as haplotype 1 to hap-
lotype 14, corresponding to the frequency at which they
occur; haplotype 1 being the most frequent.
Morphine dose and genotypes
The pharmacological observations for genotype groups
and allele carriage are shown in Table 3. The median mor-
phine dose requirements between genotype groups for the
Rs4818 polymorphism were 60, 80 and 120 mg/24 h for
the CC, CG and GG genotype groups, respectively (p =
0.042) and for the Rs4680 (Val158Met) polymorphism
the median morphine doses were 90, 80 and 60 mg/24 h
for the GG, GA and AA genotype groups, respectively (p =
0.022). For six of the SNPs (Rs5746849, Rs740603 in
intron 1, Rs6269 in intron 2, Rs2239393 in intron 3 and
Rs4818 and Rs4680 (Val158Met) in exon 4) allele carriers
showed a tendency to differences in median morphine
doses. (Table 3).Molecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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Morphine dose and haplotypes
We observed that carriers of haplotype 1, the most fre-
quent haplotype in this Caucasian population (Table 2),
needed less morphine than non-carriers, with a median
morphine dose of 60 mg/24 h for carriers versus 100 mg/
24 h for non-carriers (p = 0.006) (Table 4a). The serum
concentrations of morphine, morphine-6-glucuoride
(M6G) and morphine-3-glucuronide (M3G) reflected the
different morphine doses between haplotypes, but no dif-
ferences were statistically significant (Table 4b).
Patient symptoms including average pain, fatigue, nausea
and vomiting, dyspnea, sleep, appetite, constipation and
cognitive function were similar for carriers and non-carri-
ers of haplotype 1 (Table 5). Also the patient characteris-
tics age, gender, tumour diagnosis, performance status,
creatinine and albumin serum concentration, time since
morphine treatment started and survival time after study
were similar between the two genetic groups (Table 6). We
observed that the carriers of haplotype 1 have had the can-
cer diagnosis longer (45 months) than non-carriers of
Table 1: Catechol-O-methyltransferase (COMT) genotype frequencies, allele frequencies and allele carriage in the total of 197 cancer 
patients
SNP (region) Genotype Genotype frequencies Allele Allele frequencies Allele carriage
Rs2075507* AA 0.26 A 0.53 0.80
(promoter) AG 0.54 G 0.47 0.74
GG 0.20
Rs737866 AA 0.61 A 0.78 0.94
(intron 1) AG 0.33 G 0.22 0.39
GG 0.06
Rs7287550 CC 0.53 C 0.72 0.91
(intron 1) CT 0.38 T 0.28 0.47
TT 0.09
Rs5746849 GG 0.18 G 0.43 0.68
(intron 1) GA 0.49 A 0.57 0.82
AA 0.33
Rs740603 AA 0.31 A 0.56 0.81
(intron 1) AG 0.50 G 0.44 0.69
GG 0.19
Rs6269 AA 0.40 A 0.62 0.84
(intron 2) AG 0.44 G 0.38 0.60
GG 0.16
Rs2239393 AA 0.40 A 0.62 0.84
(intron 3) AG 0.44 G 0.38 0.59
GG 0.16
Rs4818 CC 0.41 C 0.63 0.84
(exon 4) CG 0.43 G 0.37 0.59
GG 0.16
Rs4680 (Val158Met) GG 0.22 G 0.44 0.66
(exon 4) GA 0.44 A 0.56 0.78
AA 0.34
Rs174699 CT 0.09 C 0.04 0.09
(intron 5) TT 0.91 T 0.96 100.0
Rs165728 CT 0.10 C 0.05 0.10
(untranslated region) TT 0.90 T 0.95 100.0
* Rs2075507 has recently been revised, earlier SNP number was Rs2097603M
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Table 2: COMT haplotype frequencies.
SNP position (5' to 3') Haplotype frequency
Haplotype Rs 2075507 Rs 737866 Rs 7287550 Rs 5746849 Rs 740603 Rs 6269 Rs 2239393 Rs 4818 Rs 4680 
(Val158Met)
Rs 174699 Rs 165728 n chromosomes (%)
1 G A C A A A A C A T T 136 (34.5)
2 A G C G G G G G G T T 70 (17.8)
3 A A T G G A A C A T T 33 (8.4)
4 A A T G G G G G G T T 24 (6.1)
5 G A C A A G G G G T T 18 (4.6)
6 A A T A A A A C A T T 18 (4.6)
7 G A C G G G G G G T T 10 (2.5)
8 A A C A A G G G G T T 9 (2.3)
9 A A T G G A A C G T T 9 (2.3)
10 A A C A A A A C A T T 9 (2.3)
11 A A T A A A A C G C C 8 (2.0)
12 A A T A G A A C A T T 6 (1.5)
13 G A T A A G G C G T T 4 (1.0)
14 G G C A A A A C A T T 4 (1.0)
X - - - - - ---- - - 3 6  ( 9 . 1 )
Catechol-O-methyltransferase (COMT) haplotype frequencies for the total of 197 cancer patients.Molecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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haplotype 1 (31 months) (p = 0.03; Table 6). However
there were no differences in time since morphine treat-
ment started between carriers and non-carriers of haplo-
type 1 (3.4 and 3.6 months respectively; p = 0.47).
In a multivariate stepwise linear regression analysis the
variables "time since morphine treatment started" and
haplotype 1 were shown to influence the morphine dose
(p = 0.001 and p = 0.005; Table 7). After adjusting for the
variable "time since morphine treatment started", the car-
riers of haplotype 1 still require lower morphine doses
than patients that do not carry haplotype 1. Time since
morphine treatment started is positively associated to
morphine dose, whereas the carriers of haplotype 1 is pre-
dicted to need lower doses of morphine than non-carriers
of haplotype 1 with a reduction factor of 0.71 (see discus-
sion for calculation).
Discussion
We have identified a frequent haplotype (haplotype 1) in
the COMT gene that may influence the morphine dose
requirements in cancer patients with pain. Patients who
carry haplotype 1 need lower morphine doses to relieve
pain than patients that do not carry this haplotype (p =
0.006). The carriers of haplotype 1 are also carriers of the
A allele for the Rs4680 (Val158Met) polymorphism,
which is in agreement with our earlier observation that
carriers of the Met variant of the enzyme (= A allele) need
lower morphine doses than carriers of the Val variant of
the COMT enzyme [2]. However, the effect of the A allele
for the Rs4680 (Val158Met) polymorphism is not seen for
haplotype 3 (Table 4a).
The Rs4680 (Val158Met) polymorphism is the most stud-
ied SNP in the COMT gene because the valine (Val) to
methionine (Met) substitution leads to a three-to four-
fold reduced activity of the COMT enzyme [4], hence the
Val/Val, Val/Met and Met/Met genotypes predict a high,
intermediate and low COMT enzyme activity, respec-
tively. As the COMT enzyme metabolises catecholamines,
a low COMT enzyme activity could result in an enhanced
activation of dopaminergic neurotransmission. It is
shown in animal models that the neuronal content of
enkephalin peptides is reduced by chronic activation of
dopaminerg neurotransmission [10]. Pain sensitivity is
affected by the neuronal content of enkephalin, and
reduction in the enkephalin content is shown to be fol-
lowed by an upregulation of mu opioid receptors [11].
Taken together, this can explain the influence from varia-
tion in the COMT gene on the effect of opioids in pain
treatment.
We also observed that carriers of alleles for six of the SNPs
analysed, the Rs5746849 and Rs740603 polymorphism
in intron 1, the Rs6269 polymorphism in intron 2, the
Rs2239393 polymorphism in intron 3 and the Rs4818
and Rs4680 (Val158Met) polymorphisms in exon 4 were
weakly associated to morphine dose (Table 3). The alleles
associated with the lowest morphine dose requirements
constitute part of the SNP sequence in haplotype 1, which
seems reasonable since haplotype 1 is associated with
lower morphine dose requirements in this patient cohort.
The SNPs defining a haplotype may have functional
effects on a protein if the amino acid code is changed [4],
and synonymous SNPs may have effects on the secondary
structure of mRNA [12], that could alter mRNA stability
and/or the translation of a protein [13]. SNPs may also be
associated to a phenotype without having any effects nei-
ther on the protein nor the mRNA, if it is closely linked to
another SNP exerting the real effect on the protein or
Schematic diagram of the COMT gene Figure 1
Schematic diagram of the COMT gene. Schematic diagram of the catechol-O-methyltransferase (COMT) gene, labeled with 
the 11 SNPs analysed in the present study. *Rs2075507 has recently been revised, the former SNP number was Rs2097603. 
Exon 1 and exon 2 are non-coding.Molecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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Table 3: Pharmacological observations.
SNP Genotype Morphine dose mg/24 h median 
[range]
P value Allele carriage Morphine dose mg/24 h Median 
[range]
P value
Rs2075507 AA 90 [20–420] 0.220 A 80 [20–760] 0.90
AG 70 [20-480] Not A 60 [10–660]
GG 60 [10–660] G 70 [10–760] 0.09
Not G 90 [20–420]
Rs737866 AA 70 [10–660] 0.486 A 73 [10–760] 0.26
AG 80 [20–760] Not A 90 [20–350]
GG 90 [20–350] G 80 [20–760] 0.45
Not G 70 [10–660]
Rs7287550 CC 70 [20–760] 0.862 C 78 [10–760] 0.59
CT 80 [10–410] Not C 120 [30–420]
TT 120 [30–420] T 80 [10–420] 0.91
Not T 70 [20–760]
Rs5746849 GG 115 [20–420] 0.103 G 80 [20–420] 0.57
GA 80 [20–390] Not G 65 [10–760]
AA 65 [10–760] A 70 [10–760] 0.03c
Not A 115 [20–420]
Rs740603 AA 70 [10–760] 0.099 A 70 [10–760] 0.04c
AG 80 [20–390] Not A 110 [20–420]
GG 110 [20–420] G 80 [20–420] 0.92
Not G 70 [10–760]
Rs6269 AA 70 [20–660] 0.090 A 70 [10–660] 0.03c
AG 75 [10–480] Not A 120 [20–760]
GG 120 [20–760] G 80 [10–760] 0.32
Not G 70 [20–660]
Rs2239393 AA 70 [20–660] 0.093 A 70 [10–660] 0.03c
AG 73 [10–480] Not A 120 [20–760]
GG 120 [20–760] G 80 [10–760] 0.42
Not G 70 [20–660]
Rs4818 CC 60 [10–660] 0.042 a C 70 [10–660] 0.04c
CG 80 [20–480] Not C 120 [20–760]
GG 120 [20–760] G 80 [20–760] 0.04c
Not G 60 [10–660]
Rs4680 (Val158Met) GG 90 [20–760] 0.022 b G 80 [10–760] 0.045c
GA 80 [10–480] Not G 60 [20–660]
AA 60 [20–660] A 70 [10–660] 0.07
Not A 90 [20–760]
Rs174699 CT 80 [20–480] 0.666 C 80 [20–480] 0.67
Not C 73 [10–760]
TT 73 [10–760] T 80 [10–760] -
Not T -
Rs165728 CT 80 [20–480] 0.457 C 80 [20–480] 0.46
Not C 70 [10–760]
TT 70 [10–760] T 80 [10–760] -
Not T -
a Kruskal-Wallis test for 3 independent samples; b Jonckheere Tepstra test for 3 independent samples; c Mann-Whitney U test for 2 independent 
samples.
Pharmacological observations for genotype groups and allele carriage.Molecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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Table 4: Pharmacological observations I % II
a – Pharmacological observations I.
Morphine dose and haplotype groups
Haplotype Carriage N Morphine dose mg/24 h median [range] P value
1 Yes 114 60 [10–660] 0.006 a
No 83 100 [20–760]
2 Yes 61 80 [20–410] 0.94
No 136 70 [10–760]
3 Yes 31 90 [20–420] 0.44
No 166 78 [10–760]
4 Yes 24 70 [20–420] 0.94
No 173 80 [10–760]
5 Yes 17 120 [20–760] 0.17
No 180 78 [10–660]
6 Yes 17 120 [30–200] 0.56
No 180 73 [10–760]
7 Yes 10 120 [40–290] 0.44
No 187 80 [10–760]
N = number of patients
a Mann-Whitney U test for independent samples.
b – Pharmacological observations II.
Serum concentration of morphine, M6G and M3G against haplotype groups
Haplotype Carriage N Morphine (nmol/ml) median [range] M6G (nmol/ml) median [range] M3G (nmol/ml) median [range]
1 Yes 114 51 [2–350] 310 [10–2660] 1810 [120–16200]
No 83 59 [3–1070] 349 [20–4830] 2310 [110–21250]
2 Yes 61 50 [3–330] 346 [20–2482] 1890 [120–12390]
No 136 60 [2–1070] 319 [10–4830] 2040 [110–21250]
3 Yes 31 67 [5–320] 310 [29–1690] 2200 [197–7780]
No 166 50 [2–1070] 330 [10–4830] 1992 [110–21250]
4 Yes 24 51 [3–277] 380 [20–2482] 2213 [110–12390]
No 173 57 [2–1070] 320 [10–4830] 1992 [120–21250]
5 Yes 17 80 [4–1070] 403 [20–4830] 2415 [110–21250]
No 180 52 [2–519] 325 [10–2660] 1960 [120–16200]
6 Yes 17 90 [9–230] 470 [120–1105] 3118 [1017–5481]
No 180 50 [2–1070] 318 [10–4830] 1890 [110–21250]
7 Yes 10 50 [6–220] 460 [81–1809] 1832 [490–9460]
No 187 58 [2–1070] 330 [10–4830] 2020 [110–21250]
N = number of patients; M6G = Morphine-6-glucuronide; M3G = Morphine-3-glucuronide
No statistical differences between carriers and non-carriers of the different haplotype groups for morphine, M6G and M3G serum concentrationMolecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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mRNA. The exact contribution from each SNP in haplo-
type 1 to the observed effect on morphine requirements in
the present study is not known.
In the paper we have constructed long haplotypes across
the entire COMT  gene. An alternative approach would
have been to construct haplotypes defined by haploblock
boundaries. The latter approach is based on including
only SNPs that have a very high probability of being
inherited together (visualized by the value of D' or r2
which are correlation factors between SNPs) and as a con-
sequence limiting the gene distance to which SNPs catego-
rize into haplotypes. According to literature the COMT
gene consists of at least three haploblocks in Caucasians
[3,14] and there is consistency between ethnic groups, so
the haploblocks is likely to be present also in a Norwegian
population. The division of genes into haploblocks limits
the number of haplotypes present in the population and
thereby increases the number of individuals that fall into
each different haplotype group. When analysing long hap-
lotypes across the entire gene fewer individuals in the
population will be carriers, but more information will be
gained from the effect of combination of SNPs and in that
sense long haplotypes may be more biologically relevant.
Any sizes of haplotypes will be of more scientifically inter-
ests than analyses of SNPs considered one by one.
A cancer population is a heterogeneous group and prone
to be influenced from several possible confounders such
as severity of disease, organ dysfunction and treatment of
other drugs. Therefore, we analysed for possible con-
founding factors that could influence the need for mor-
phine in cancer pain. We found no differences between
carriers and non-carriers of haplotype 1 for patients'
Table 5: Patient symptoms.
Haplotype 1 P value a
Carriers Non-carriers
BPI average pain 3.5 (2.6) 3.9 (2.2) 0.26
Fatigue (EORTC score) 64.5 (23.5) 68.6 (23.1) 0.28
Nausea and vomiting (EORTC score) 26.6 (25.9) 27.0 (28.5) 0.77
Dyspnea (EORTC score) 36.6 (32.5) 34.4 (34.7) 0.80
Sleep (EORTC score) 35.3 (36.0) 32.8 (35.2) 0.58
Appetite (EORTC score) 53.2 (37.6) 54.3 (37.2) 0.95
Constipation (EORTC score) 54.5 (37.9) 55.7 (38.4) 0.77
Mini mental examination sum score 26.1 (3.4) 25.6 (4.0) 0.66
a Mann-Whitney U test for 2 independent samples
Patient symptoms for carriers and non-carriers of haplotype 1.
Table 6: Patient demographics.
Haplotype 1 P value
Carriers Non-carriers
Age 63 (13) 64 (12) 0.68
Gender:
Male 68 (60%) 44 (53%) 0.38
Female 46 (40%) 39 (47%)
Tumour diagnosis:
Urological 38 19 0.80
Lung 20 17
Breast 25 19
Gastrointestinal 7 10
Haematological 10 6
Others 14 12
Karnofsky performance status 67 (14) 66 (13) 0.36
Creatinine serum (μmol/l) 86 (28) 87 (39) 0.48
Albumin serum (g/l) 33 (5) 32 (5) 0.12
Time since diagnosis (months) 45 (52) 31 (43) 0.03a
Time since morphine treatment started (months) 3.4 (7.8) 3.6 (5.9) 0.47
Survival time after study (months) 5.7 (6.2) 4.8 (5.5) 0.23
Numbers in the table are given as mean (SD) or absolute numbers (%)
a Mann-Whitney U test for 2 independent samples
Patient demographics for carriers and non-carriers of haplotype 1.Molecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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symptoms or for patients' demographics, except from the
time since diagnosis. There was a tendency that carriers of
haplotype 1 have had a cancer diagnosis for a longer time
than non-carriers of the haplotype (Table 6). Theoreti-
cally, patients with a diagnosis for a long time (that is the
patients carrying the haplotype 1) should need more mor-
phine due to more advance cancer disease. In our cohort
the carriers of haplotype 1 need less morphine than non-
carriers. Thus, a potential bias from the skewed distribu-
tion of time since cancer diagnosis is that the observed dif-
ference between haplotypes is lower that the true
difference between haplotypes. However, in order to fur-
ther explore if time since diagnosis was an independent
predictor of morphine dose we included potential con-
founding factors in a multivariate analysis. This analysis
showed that only "haplotype 1" and "time since mor-
phine treatment started" were predictors for morphine
dose. Regression analysis is usually linear, where b is the
slope of the graph and gives the change in value of one
outcome (e.g. morphine dose), per unit change in the
other (e.g. months of morphine treatment). In our regres-
sion the association is not linear because we used the log-
arithm (log10) of the 24 hour morphine dose as the
dependent variable. Therefore, for each month of mor-
phine treatment, the predicted 24 hour morphine dose
increases by a factor of 10(b × months) which translates to
that the dose on average increases by 43% every 12
months (100.013 × 12). Patient carrying haplotype 1 is pre-
dicted to need less morphine to relieve pain than a patient
not carrying haplotype 1, with a reduction factor of 10(b)
= 10(-0.147) = 0.713. In other words, if a patient, not carry-
ing haplotype 1 need 100 mg of morphine to relieve pain,
a patient carrying haplotype 1 is predicted to need 71 mg
of morphine to relieve similar pain. The difference we
observe in the median morphine dose between non-carri-
ers and carriers of haplotype 1 is of similar order of mag-
nitude, 100 mg versus 60 mg of the 24 hour morphine
dose respectively (Table 4a). Experimental studies includ-
ing healthy volunteers give more controlled experimental
conditions due to less potential confounders. However,
clinical studies including cancer patients, such as this
study and the study by Ross et al.,[9] are needed to observe
if genetic variability do influence morphine treatment in
the patients actually receiving the drug. The best effort in
a clinical population is therefore to include potential con-
founders in the analyses and interpret findings within the
clinical context.
Ross et al., analysed the COMT gene and its association
with the central side effects of morphine in a cancer
patient cohort. They found that a haplotype present in
10.4% of the population was associated to drowsiness
and confusion or hallucination [9]. SNPs in the promoter
region and in the intron 1 region define this haplotype
and the authors suggest that it is this region of the COMT
gene that is of interest in order to explain clinical effect
from the COMT enzyme. Alterations in the promoter and
intronic region of the gene can influence the regulation of
gene expression. Therefore, polymorphisms in these
regions might be as important as functional SNPs in cod-
ing regions. The Ross study did not find any associations
between the Rs4680 (Val158Met) polymorphism and
central side effects of morphine [9]. Haplotype 1 in the
present study is not identical to the haplotype that Ross
and co-authors observed to be associated to central side
effects of morphine. However, the haplotypes identified
as important by Ross et al., and haplotype 1 in our study
are related as 7 of 10 possible SNP positions from the
Rs5746849 polymorphism in intron 1 to the UTR' region
carry the same allele and both haplotypes carry the A
allele at the Rs4680 (Val158Met) polymorphism. An
explanation for the discrepancy of the haplotypes might
be that efficacy for pain relief and risks of adverse effects
have different relationships to genotypes.
The need for morphine is a result of both the efficacy of
morphine and influenced by the patients' pain percep-
tion. Patients can experience variable pain from a given
nociceptive stimuli. Therefore genetic variability related to
opioid efficacy as studied in the present study is closely
linked to genetic variability related to pain perception.
Diatchenko et al., have investigated COMT gene variabil-
ity and association to pain responses [3]. They identified
three haplotypes in the COMT gene strongly associated to
pain sensitivity and they designated the different haplo-
types as low pain sensitivity (LPS), average pain sensitivity
(APS) and high pain sensitivity (HPS) haplotypes. Four
SNPs (Rs6269, Rs4633, Rs4818 and Rs4680) constitute
these haplotypes, of which three of the SNPs (Rs6269,
Rs4818 and Rs4680) are included in our analyses. How-
ever, Diatchenko et al., did not include the region in
intron 1 or the promoter regions, the region which the
study by Ross and co-authors [9] believe to be the func-
tional region of interest in the COMT gene. A direct com-
parison with our study is difficult because we have
included 11 SNPs in our haplotype analyses while Diatch-
enko et al., focused on four SNPs. Kim et al., have also
Table 7: Regression analysis. Morphine dose regression analysis
b SE P value
Haplotype 1 -0.147 0.051 0.005
Time since morphine treatment started 0.013 0.004 0.001
Constant 1.95 0.042
The logarithm (log10) of the 24 hour oral morphine dose was the 
dependent variable in this regression analysis. The regression 
coefficient, b, is an estimate of the parameter beta. SE = standard 
errorsMolecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
Page 10 of 12
(page number not for citation purposes)
investigated  COMT  gene variability and association to
pain responses and found that the Rs740603 SNP was
associated with maximum post-operative ratings of pain.
Even though the comparison between Diatchenko et al.,
[3] and Kim et al., [8] with our findings is important, it is
also complicated because we investigate the morphine
efficacy while they are studying the genetics of pain sensi-
tivity. However, one agreement between the different
studies is that the Rs4680 (Val158Met) polymorphism is
not the sole explanation of why COMT seem to contribute
to the effect on pain perception or opioid efficacy as first
reported by Zubieta et al., [1] and Rakvag et al., [2], respec-
tively.
In the present study the serum concentrations of mor-
phine, morphine-6-glucuoride (M6G) and morphine-3-
glucuronide (M3G) reflected the different morphine
doses between haplotypes (Table 4b), but did not reach
statistical significance as seen for the morphine dose. The
interindividual variation of serum concentrations is more
pronounced than for the morphine doses. Consequently,
a larger effect size or an increased number of patients are
needed to reach a statistical significance for an observed
difference between serum concentrations.
Numerous SNPs have been detected in the COMT gene
and 22 of the most frequent SNPs have been analysed
regarding different aspects of pain and opioid responses
[2,3,8,9], so the analyses of 11 SNPs in our study do not
cover all genetic variation in the COMT gene. However, as
many SNPs are tightly linked within haploblocks, most
genetic variability is captured if the selections of SNPs are
chosen to represent the different haploblocks building the
entire gene [15], which is done in the present study.
In the present study we have carried out several compari-
sons. Multiple test correction, as the Bonferroni, is used
when tests are independent and is therefore highly con-
servative. In a genetic association study where SNPs usu-
ally are partly linked to each other, as is the case for the
COMT gene, a conservative multiple test correction lead
to missing real differences [16,17]. Also, in our study the
haplotype analyses is the primary outcome and then as a
consequence we do not consider all null hypotheses to be
of equally importance [17]. In addition to the haplotype
analyses, differences at genotype level and allele level are
presented in this study, but differences at 0.01 < p < 0.05
are interpreted with caution and reported as weak associ-
ations between genetic groups.
Conclusion
This study suggest that genetic variability in the COMT
gene influence the efficacy of morphine in cancer pain
patients, and that increased understanding of this varia-
bility is reached by expanding from analyses of single
SNPs to haplotype constructions and analyses.
Materials and methods
Ethics
The study was carried out in accordance to the principles
of the Helsinki declaration. The Regional Committee for
Medical Research Ethics, Health Region IV, Norway,
approved the study. All patients gave their oral and writ-
ten informed consent before inclusion in the study.
Subjects
We investigated the same cohort as previously described
by Rakvag et al., [2]. Two hundred and seven patients were
included in the original study, but blood for further
genetic analyses was not available for 10 patients. There-
fore, 197 patients were available for further genotyping
and included in our analyses. All 197 patients were Cau-
casians, and all received scheduled oral morphine for can-
cer pain treatment.
Assessments
Pain was measured using the item "average pain" during
the last 24 hours in the Brief Pain Inventory (BPI) ques-
tionnaire. The patients rated pain on an 11-point numeric
scale, where 0 represents "no pain" and 10 represents
"pain as bad as you can imagine". The BPI is developed for
the use in cancer pain patients, validated in Norwegian,
and recommended by the European Association of Pallia-
tive Care for use in clinical studies [18-20]. The European
Organization for Research and Treatment of Cancer core
quality-of-life questionnaire (EORTC QLQ-C30) version
3.0 was used to assess the patients' nausea/vomiting, con-
stipation, fatigue, sleep, appetite and dyspnea [21]. Cog-
nitive function was assessed with the Mini Mental State
(MMS) examination. The MMS score ranges from 0 to 30,
higher scores meaning better cognitive function [22]. The
patients' functional status was assessed by the Karnofsky
performance status [23]. Survival time, time since start of
morphine, cancer diagnoses and opioid doses were
obtained from the patients' hospital records.
Blood samples and pharmacogenetic analyses
Collection of blood samples and determination of serum
concentration of morphine and its metabolites (mor-
phine-6-glucuronide and morphine-3-glucuronide) were
done as described in a previous work from our group [24].
Creatinine serum concentrations and albumin serum con-
centrations were measured using standard analytical
methods.
The genotyping was performed at the Clinical Genomics
Group, Imperial College in London, UK. The selection of
SNPs for this study and primer sequences for sequence
specific polymerase chain reaction (SSP-PCR) areMolecular Pain 2008, 4:64 http://stephenslab.uchicago.edu/home.html
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described in a study by Ross and co-authors investigating
another cohort and another primary outcome [9]. The
selection was based upon frequency of SNP, position in
gene and what was known in the literature at the time
research was planned. Of the 13 polymorphic SNPs
included in Ross and co-authors' study, the rs174680 and
the rs7290221 polymorphisms in intron 1, were not ana-
lysed in our patient cohort due to very tight linkage with
the rs7287550 polymorphism and the rs5746849 poly-
morphism respectively. As the reaction of the Rs4633 pol-
ymorphism did not work very well, we excluded this
polymorphism in the present study, but included the
Rs4818 polymorphism in exon 4, which had not been
analysed in the previous Ross study. Together, 11 SNPs
were genotyped in the present study.
Genomic DNA was isolated from 50 to 200 μL EDTA
blood on a MagNA Pure LC (Roche Diagnostics Scandina-
via AB, Bromma, Sweden) using the MagNA Pure LC DNA
Isolation Kit I applying the manufacturers high perform-
ance protocol. Purified genomic DNA was eluted in 100
μL antiseptic water and stored at -20°C. Genotypes were
determined using sequence specific primers in a polymer-
ase chain reaction (SSP-PCR) [25]. A sequence specific
primer and a consensus primer produce a DNA product of
known size in this PCR. The sequence specific primer has
a mismatch at the 3' end which is designed to identify
each genotype variant. The PCR were carried out as
described in Ross et al. [26]. PCR products were then elec-
trophoresed on 1.5% agarose gels (Bioline Ltd, London,
UK) containing 0.14 mg/mL ethidium bromide (Sigma
Ltd, Poole, UK), at 200 volts/cm2 in 0.5% tris borate EDTA
buffer (Sigma Ltd, Poole, UK). Products were visualised
with a UV illuminator and photographed with a Polaroid
camera. The presence of an allele specific band of the
expected size, in conjunction with a control band was
used to identify an allele.
Construction of haplotypes
Genotype and allele frequencies and allele carriage were
calculated and checked for Hardy-Weinberg equilibrium.
Haplotypes were constructed from genotype information
from each patient using the computer program Phase
http://stephenslab.uchicago.edu/home.html[27,28].
Statistical analyses
The statistical software SPSS for windows v. 14.0 was used
to run non-parametric tests and to run a stepwise linear
regression analysis. Because the COMT  alleles are
expected to be codominant with respect to the Rs4680
(Val158Met) polymorphism and COMT enzyme activity,
we used the Jonckheere-Terpstra test for comparison
between genotype groups, working with a hypothesis that
μ1 ≤ μ2 ≤ μ3 (or the opposite μ1 ≥ μ2 ≥ μ3) [29]. For all other
SNPs we used the Kruskal-Wallis test for comparison
between genotype groups. We used the logarithm (log10)
of the 24 hour morphine dose as the dependent variable
in the regression analyses because the 24 hour morphine
dose, as expected, did not display a normal distribution.
The analysis was a stepwise enter linear regression with a
criterion for removal of a variable of p > 0.1. The variables
included in the regression analysis as independent varia-
bles were: haplotype 1, age, gender, tumour diagnosis,
Karnofsky performance status, creatinine and albumin
serum concentration, time since diagnosis, time since
morphine treatment started, survival time after study, BPI
average pain score, EORTC score for fatigue, nausea and
vomiting, dyspnea, sleep, appetite and constipation, and
finally the sum score for the Mini mental examination
measuring cognitive function.
Interpretation of p values in this study is done with cau-
tion considering the multiplicity of tests carried out.
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